A phase 2/3 multicentre, open-label, randomised study evaluating safety and antiviral effect of elvitegravir (EVG) administered with darunavir/ritonavir (DRV/r) compared to current standard antiretroviral therapy in HIV-1 infected, virologically suppressed paediatric participants.

Trial Profile

A phase 2/3 multicentre, open-label, randomised study evaluating safety and antiviral effect of elvitegravir (EVG) administered with darunavir/ritonavir (DRV/r) compared to current standard antiretroviral therapy in HIV-1 infected, virologically suppressed paediatric participants.

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 23 Jun 2017

At a glance

  • Drugs Elvitegravir (Primary) ; Darunavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms SMILE
  • Most Recent Events

    • 23 Jun 2017 This trial has been suspended in Germany as per European Clinical Trials Database record
    • 10 Jun 2017 Biomarkers information updated
    • 11 Feb 2017 This trial has been suspended in Spain as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top